Venatorx Pharmaceuticals, Inc.

Venatorx Pharmaceuticals, Inc. company information, Employees & Contact Information

Venatorx Pharmaceuticals is a private pharmaceutical company that is focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections.

Company Details

Employees
56
Founded
-
Address
74 E Swedesford Road, Suite 100,united States
Phone
610-644-8935
Email
co****@****orx.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Malvern, Pennsylvania
Looking for a particular Venatorx Pharmaceuticals, Inc. employee's phone or email?

Venatorx Pharmaceuticals, Inc. Questions

News

Discovery of VNRX-9945, a Potent, Broadly Active Capsid Assembly Modulator as a Clinical Candidate for the Treatment of Chronic Hepatitis B Virus Infection | ACS Medicinal Chemistry Letters - ACS Publications

Discovery of VNRX-9945, a Potent, Broadly Active Capsid Assembly Modulator as a Clinical Candidate for the Treatment of Chronic Hepatitis B Virus Infection | ACS Medicinal Chemistry Letters ACS Publications

Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic - GlobeNewswire

Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic GlobeNewswire

Overcoming Metallo-β-Lactamases: A Review of Cefepime-Taniborbactam - Pharmacy Times

Overcoming Metallo-β-Lactamases: A Review of Cefepime-Taniborbactam Pharmacy Times

Venatorx Pharmaceuticals Announces Changes to Executive Leadership - Business Wire

Venatorx Pharmaceuticals Announces Changes to Executive Leadership Business Wire

Basilea secures rights to Venatorx’s antibiotic for complicated UTIs - Pharmaceutical Technology

Basilea secures rights to Venatorx’s antibiotic for complicated UTIs Pharmaceutical Technology

Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for Cefepime-Taniborbactam in 96 Countries - PR Newswire

Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for Cefepime-Taniborbactam in 96 Countries PR Newswire

Basilea nets rights to Venatorx's Phase III-ready oral antibiotic combo - FirstWord Pharma

Basilea nets rights to Venatorx's Phase III-ready oral antibiotic combo FirstWord Pharma

FDA requests additional data regarding cefepime-taniborbactam for cUTI - Urology Times

FDA requests additional data regarding cefepime-taniborbactam for cUTI Urology Times

Venatorx, Melinta's BARDA-funded antibiotic combo falls short with manufacturing-related rejection - Fierce Pharma

Venatorx, Melinta's BARDA-funded antibiotic combo falls short with manufacturing-related rejection Fierce Pharma

Melinta Therapeutics Partnering with Venatorx Pharmaceuticals on Commercializing Antibiotic - Contagion Live

Melinta Therapeutics Partnering with Venatorx Pharmaceuticals on Commercializing Antibiotic Contagion Live

Malvern-Based Venatorx Enters Global Deal with Switzerland Pharma Company - VISTA.Today

Malvern-Based Venatorx Enters Global Deal with Switzerland Pharma Company VISTA.Today

Published data show superiority of cefepime–taniborbactam over meropenem for cUTI - Urology Times

Published data show superiority of cefepime–taniborbactam over meropenem for cUTI Urology Times

Venatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam - Business Wire

Venatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam Business Wire

Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections | Journal of Medicinal Chemistry - ACS Publications

Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections | Journal of Medicinal Chemistry ACS Publications

FDA Issues a CRL for Venatorx Pharmaceuticals’ Antibiotic for Treatment of Complicated UTI - Contagion Live

FDA Issues a CRL for Venatorx Pharmaceuticals’ Antibiotic for Treatment of Complicated UTI Contagion Live

Venatorx and Menarini sign commercial deal for antibiotic - Pharmaceutical Technology

Venatorx and Menarini sign commercial deal for antibiotic Pharmaceutical Technology

Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes - ACS Publications

Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes ACS Publications

Venatorx Pharmaceuticals Names Robert Waltermire, Ph.D. Senior Vice President, CMC - Business Wire

Venatorx Pharmaceuticals Names Robert Waltermire, Ph.D. Senior Vice President, CMC Business Wire

Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes | Journal of Medicinal Chemistry - ACS Publications

Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes | Journal of Medicinal Chemistry ACS Publications

Basilea inks antibiotic deal with Venatorx - The Pharma Letter

Basilea inks antibiotic deal with Venatorx The Pharma Letter

After 'Challenging but Rewarding Journey', CEO of Malvern's Venatorx Pharmaceuticals Steps Down - VISTA.Today

After 'Challenging but Rewarding Journey', CEO of Malvern's Venatorx Pharmaceuticals Steps Down VISTA.Today

Swiss pharma company Basilea bets up to $325M on Venatorx's experimental UTI treatment - The Business Journals

Swiss pharma company Basilea bets up to $325M on Venatorx's experimental UTI treatment The Business Journals

Cefepime-Taniborbactam Gets Priority Review for Complicated UTI - Renal and Urology News

Cefepime-Taniborbactam Gets Priority Review for Complicated UTI Renal and Urology News

FDA accepts NDA for cefepime-taniborbactam for complicated UTIs - Contemporary OB/GYN

FDA accepts NDA for cefepime-taniborbactam for complicated UTIs Contemporary OB/GYN

One up, one down: Allecra scores FDA nod for antibiotic combo after Venatorx hit with rejection - Fierce Pharma

One up, one down: Allecra scores FDA nod for antibiotic combo after Venatorx hit with rejection Fierce Pharma

VenatoRx Pharma | Biotechnology | The Pharmaletter - The Pharma Letter

VenatoRx Pharma | Biotechnology | The Pharmaletter The Pharma Letter

Venatorx co-founder Christopher Burns steps down as CEO - The Business Journals

Venatorx co-founder Christopher Burns steps down as CEO The Business Journals

VenatoRx Pharmaceuticals named ‘Best Places to Work’ Second Year in a Row - BioSpace

VenatoRx Pharmaceuticals named ‘Best Places to Work’ Second Year in a Row BioSpace

VenatoRx Pharmaceuticals named a 2018 Best Places to Work - BioSpace

VenatoRx Pharmaceuticals named a 2018 Best Places to Work BioSpace

Christopher Burns, Daniel Pevear and Luigi Xerri - Main Line Today

Christopher Burns, Daniel Pevear and Luigi Xerri Main Line Today

Venatorx turns screws on cUTI, proving 'Certain' superiority to standard therapy - BioWorld MedTech

Venatorx turns screws on cUTI, proving 'Certain' superiority to standard therapy BioWorld MedTech

Zone3 Venator-X swimming goggles review - 220 Triathlon

Zone3 Venator-X swimming goggles review 220 Triathlon

Top Venatorx Pharmaceuticals, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant